YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Also announces Agreement with Oak Hill Financial and DTC Eligibility OTTAWA, Ontario, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (OTCQB: VIRMF) ("Viridian" or the "Company") reports additional assay results from its…
OTTAWA, Ontario, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN, OTCQB: VIRMF) ("Viridian" or the "Company") is pleased to announce that, further to its news release dated August 24, 2026, it has closed its previously a…
OTTAWA, Ontario, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Assays are now pending from the first diamond drill holes completed as part of Viridian Metals Inc.'s (CSE: VRDN) (OTCQB: VIRMF) 2026 drill program at the Kraken project in Labrador. The i…
The Graves' ophthalmopathy market is expected to witness steady growth over the coming years, driven by the rising prevalence of autoimmune thyroid disorders, improved disease awareness, and earlier diagnosis. Additionally, the recent appr…
Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the 10 affordable biotech stocks to buy right now. On June 30, Goldman Sachs increased its target price for Viridian Therapeutics Inc. (NASDAQ:VRDN) from $35 to $39, implying an adjusted u…
What to make of the markets today? The biggest story in recent months has been the conflict in the Middle East and its effect on oil prices. After pulling back for a while, crude has started moving higher again as geopolitical tensions rai…
With EPS growth for the next five years forecasted at 67.57%, Viridian Therapeutics, Inc. (NASDAQ:VRDN) is among the 12 Best Quality Stocks to Buy and Hold for the Next Decade. On June 30, Wedbush analyst Laura Chico raised the firm's pric…
Shares of Viridian Therapeutics VRDN have gained 6.3% over the past week compared with the industry's 5.5% growth. The upside came after the company announced that the FDA approved veligrotug, an IGF-1R antagonist, under priority review fo…
The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.18%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.59%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +2.25%. September E-mini S&P futures (ESU26) rose +1.20%, and Sept…
The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.18%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.59%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +2.25%. September E-mini S&P futures (ESU26) rose +1.20%, and Sept…
The S&P 500 Index ($SPX) (SPY) is up +0.73% today; the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.64%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.08%. September E-mini S&P futures (ESU26) are up +0.76%, and September E-mini N…
The S&P 500 Index ($SPX) (SPY) today is up +0.59%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.64%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.67%. September E-mini S&P futures (ESU26) are up +0.73%, and September E-mini N…
The S&P 500 Index ($SPX) (SPY) is up +0.73% today; the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.64%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.08%. September E-mini S&P futures (ESU26) are up +0.76%, and September E-mini N…
The S&P 500 Index ($SPX) (SPY) today is up +0.59%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.64%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.67%. September E-mini S&P futures (ESU26) are up +0.73%, and September E-mini N…
Investing.com - U.S. stock futures rose on Monday as investors assessed reports that Washington and Tehran had agreed to halt recent hostilities around the Strait of Hormuz and resume diplomatic talks, easing fears of broader disruptions i…
[Woman at home investing in the stock market using an app on her tablet] ToucanStudios Stock futures pushed into the green Monday morning as investors drew confidence from a reported pause in direct military actions between the U.S. and Ir…
[FDA Headquarters] Viridian Therapeutics (VRDN [https://seekingalpha.com/symbol/VRDN]) on Saturday launched its first commercial product, Lumvoa, soon after the U.S. FDA approved the intravenous therapy for thyroid eye disease, a rare auto…
(RTTNews) - Viridian Therapeutics, Inc. (VRDN) announced that the U.S. FDA has approved Lumvoa for the treatment of thyroid eye disease, marking the company's first commercial product and a major milestone in its transition to a commercial…
Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the best low priced stocks to buy for the next 3 years. On May 6, Viridian Therapeutics announced the pricing of upsized concurrent public offerings totaling $350 million in aggregate gros…
OTTAWA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- Viridian Metals (CSE: VRDN) (“Viridian” or the “Company”) will commence a minimum 50-hole drill program in early June at its Kraken Copper-Nickel Project in Labrador, aimed at defining the…
Key Points HighVista Strategies sold 238,243 shares of Viridian Therapeutics; the estimated trade size was $7.08 million based on average closing prices from January through March 2026. The quarter-end position value decreased by $8.97 mil…
HighVista Strategies reported a sale of 238,243 shares of Viridian Therapeutics(NASDAQ:VRDN) in its May 15, 2026, SEC filing, an estimated $7.08 million trade based on quarterly average pricing. What happened According to a SEC filing date…
Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the 10 Stocks Turning Heads With Double-Digit Gains. Viridian Therapeutics extended gains for a second day on Tuesday, soaring 33.36 percent to close at $18.75 apiece, as investor sentimen…
Viridian Therapeutics unveiled solid results Tuesday for its experimental eye disease treatment, a potential rival to Amgen. Continue Reading
medical research 3 ©Tima Miroshnichenko Regulatory milestones and late-stage clinical progress position the company ahead of a key FDA decision in June. Viridian Therapeutics, Inc. (NASDAQ:VRDN) reported first-quarter 2026 results alongsid…
Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the 10 oversold small cap stocks to buy now. On April 21, Truist reduced the price target on Viridian Therapeutics Inc. (NASDAQ:VRDN) from $36 to $33 while maintaining a Buy rating on the…
Viridian Therapeutics, Inc. (NASDAQ:VRDN) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock posted a 12.72% increment from a year ago, and a 51.76% year-to-date decline. Based on consensus, Wall Street anal…
What happened According to an SEC filing dated April 20, 2026, Kopp Family Office, LLC, reduced its stake in Viridian Therapeutics(NASDAQ:VRDN) by 117,878 shares during the first quarter. The estimated value of the transaction was $3.5 mil…
In this article, we will look at the 5 Best Small-Cap Biotech Stocks According to Hedge Funds. Please visit 10 Best Small-Cap Biotech Stocks According to Hedge Funds if you’d like to see an extended list and methodology behind it. 5. Nuvat…
Viridian Therapeutics, Inc. (NASDAQ:VRDN) is one of the most oversold healthcare stocks to invest in. Truist cut the price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) to $36 from $40 on April 8 but maintained a Buy rating on the sh…
We recently compiled a list of the 10 Best Beaten Down Stocks to Invest in According to Analysts. Viridian Therapeutics, Inc. is among the best 52-week low stocks on our list. TheFly reported on April 13 that Evercore ISI reduced its price…
OTTAWA, Ontario, April 16, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) ("Viridian" or the "Company") wishes to clarify the disclosure in its press release dated April 15, 2026 regarding its marketing services agreement with O…
OTTAWA, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) ("Viridian" or the "Company") is pleased to announce that it has entered into a marketing services agreement (the "Agreement") effective April 15, 2026 wi…
Truist lowered the firm’s price target on Viridian Therapeutics (VRDN) to $36 from $40 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in Biotech. Reactivity to regulatory and policy shifts ac…
OTTAWA, April 08, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) reports that it has been awarded $225,000 under the Junior Exploration Assistance (“JEA”) program, representing the maximum funding a…
Stifel analyst Alex Thompson notes that Amgen (AMGN) announced positive topline results for the Phase 3 on-body infusion study of Tepezza achieving a 77% rate of proptosis response, which comes in higher on both an absolute and placebo-adj…